Myeloma: FDA Approves Lenalidomide as Maintenance After Auto-HCT

Share this content:
The FDA has approved lenalidomide as maintenance therapy following autologous hematopoietic cell transplantation for multiple myeloma.
The FDA has approved lenalidomide as maintenance therapy following autologous hematopoietic cell transplantation for multiple myeloma.

The U.S. Food and Drug Administration (FDA) has approved lenalidomide as maintenance therapy following autologous hematopoietic cell transplantation for patients with multiple myeloma.1

The current approval was based on findings from 2 phase 3 trials that evaluated the efficacy and safety of lenalidomide maintenance therapy after autologous HCT in patients with multiple myeloma. The CALGB 100104 (ClinicalTrials.gov Identifier: NCT00114101) and IFM 2005-02 ClinicalTrials.gov Identifier: NCT00430365) trials demonstrated a significant 62% (hazard ratio, 0.38; 95% CI, 0.27-0.54; P < .001) and 50% (hazard ratio, 0.50; 95% CI, 0.39-0.64; P < .001) reduction in the risk of progression or death, respectively, for patients treated with lenalidomide compared with those who received placebo.

In the CALGB trial, median overall survival was 9.3 years with lenalidomide vs 7 years with no maintenance; in the IFM trial, median survival was 8.8 and 7.3 years, respectively.

The safety profile of lenalidomide in these trials was consistent with previous reports. The most frequently reported grade 3 to 4 adverse event was neutropenia, affecting 56% of the overall population. Investigators also observed an increased incidence of second primary malignancies among lenalidomide-treated patients, with 7.5% of patients who received lenalidomide developing second primary malignancies vs 3.3% in the placebo group.

The recommended dose and schedule for this lenalidomide indication is 10 mg orally once daily continuously on days 1 to 28 of each 28-day cycle.

RELATED: Multiple Myeloma: Survival Hinges on Treatment Facility Volume

The expanded indication makes lenalidomide the only treatment approved for maintenance therapy after autologous HCT in patients with multiple myeloma. 

Reference

  1. FDA expands indication for Revlimid (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT) [news release]. Summit, NJ: Celgene; February 22, 2017. http://ir.celgene.com/releasedetail.cfm?ReleaseID=1014013. Accessed February 23, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters